ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 518

The Occurrence of Shingles and the Effect of Zoster Vaccination with the Use of Methotrexate in Rheumatoid Arthritis Patients

Antony Lin1, Qiaowu Li2, Jiaxiao Shi2, Serena Lin3, Danielle Wang4, Jenny Wan5, Kevin Lee3, Hung-Fu Tseng2 and TC Cheetham6, 1Southern California Permanente Medical Group, Pasadena, CA, 2Department of Research and Evaluation, Kaiser Permanente, Pasadena, CA, 3Stanford University, Stanford, CA, 4UCI Medical Center, Irvine, CA, 5Kaiser Permanente Drug Information Services - California Regions, Downey, CA, 6Western University of Health Sciences, Pomona, CA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: methotrexate (MTX) and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster I: Comorbidities and Adverse Events; Efficacy and Safety of Small Molecules

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:  

To investigate the efficacy and safety of zoster vaccines administered in rheumatoid arthritis(RA) patients taking methotrexate(MTX).

Methods:  

By reviewing data through the Kaiser Permanente electronic medical record (EMR) retrospectively, we identified 893 adult RA patients who received zoster vaccination between January 1, 2007 and December 31, 2012 and had at least 2 RA diagnoses documented within one year prior to the vaccination date.   Patients treated with any biologic DMARDs within 6 months prior to the index dates were excluded.  The cohort was followed until the occurrence of zoster infection, disenrollment, death or the end of study, whichever came first.  The primary outcome, vaccination safety, was measured by time to occurrence of zoster infections within 42 days after zoster vaccines administered.  The secondary outcome, vaccine efficacy, measured by time to occurrence of zoster infections (after day 42) until the end of follow-up period, was studied among those who maintain the treatment during follow-up period (n=762).  Dosage effect was also analyzed among those taking MTX (n=342) by comparing patients taking >=25mg/week and those taking 22.5mg/week or less.  Cox proportional model was used to analyze hazard ratios between groups.

Results:

Among 893 RA patients who were given zoster vaccines, 366 patients were taking MTX within 6 months prior to the zoster vaccination and 527 patients were not taking MTX.  At baseline, 707(79%) patients were female with a mean age of 70.1 (SD: .5) and disease duration of 6.6 (3.9) years.   The analysis showed that the rate of zoster infection was 0.13 per 1000-person day in the MTX group and the rate was 0.23 per 1000-person day in the non-MTX group.  We found no significant statistical difference in the rate of zoster infections within the first 42 days of vaccination with adjusted hazard ratio of .50(95% CI 0.09-2.69, p-value=0.42).  During the subsequent follow-up period, 742 patients continued their baseline treatment.  The rate of zoster infection was 15.9 per 1000-person year in the MTX group and the rate was 18.6 per 1000-person year in the non-MTX group with the adjusted hazard ratio 0.79(95% CI 0.47-1.33, p-value=0.37).  Among the 334 patients taking MTX, 292 patients were taking a dose of 22.5 mg or under while 42 were taking the dose of 25mg or more.  The final analysis from the model showed no significant difference in dosage effect, the adjusted hazard ratio was 0.34(95% CI 0.04-2.54, p-value=0.29). 

Conclusion:

Zoster vaccination is safe to be given to RA patients taking MTX regardless of the dosage.  The vaccination is equally effective in RA patients taking MTX and not taking MTX. 


Disclosure: A. Lin, None; Q. Li, None; J. Shi, None; S. Lin, None; D. Wang, None; J. Wan, None; K. Lee, None; H. F. Tseng, None; T. Cheetham, Bristol-Myers Squibb, 2.

To cite this abstract in AMA style:

Lin A, Li Q, Shi J, Lin S, Wang D, Wan J, Lee K, Tseng HF, Cheetham T. The Occurrence of Shingles and the Effect of Zoster Vaccination with the Use of Methotrexate in Rheumatoid Arthritis Patients [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/the-occurrence-of-shingles-and-the-effect-of-zoster-vaccination-with-the-use-of-methotrexate-in-rheumatoid-arthritis-patients/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-occurrence-of-shingles-and-the-effect-of-zoster-vaccination-with-the-use-of-methotrexate-in-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology